Statistics for A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

Total visits

views
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours 0

Total visits per month

views
February 2025 0
March 2025 0
April 2025 0
May 2025 0
June 2025 0
July 2025 0
August 2025 0